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Abstract
Background: Icodextrin is a high molecular weight, starch-derived glucose polymer, which is
capable of inducing sustained ultrafiltration over prolonged (12–16 hour) peritoneal dialysis (PD)
dwells. The aim of this study was to evaluate the ability of icodextrin to alleviate refractory,
symptomatic fluid overload and prolong technique survival in PD patients.
Methods: A prospective, open-label, pre-test/post-test study was conducted in 17 PD patients (8
females/9 males, mean age 56.8 ± 2.9 years) who were on the verge of being transferred to
haemodialysis because of symptomatic fluid retention that was refractory to fluid restriction, loop
diuretic therapy, hypertonic glucose exchanges and dwell time optimisation. One icodextrin
exchange (2.5 L 7.5%, 12-hour dwell) was substituted for a long-dwell glucose exchange each day.
Results: Icodextrin significantly increased peritoneal ultrafiltration (885 ± 210 ml to 1454 ± 215
ml, p < 0.05) and reduced mean arterial pressure (106 ± 4 to 96 ± 4 mmHg, p < 0.05), but did not
affect weight, plasma albumin concentration, haemoglobin levels or dialysate:plasma creatinine
ratio. Diabetic patients (n = 12) also experienced improved glycaemic control (haemoglobin Alc
decreased from 8.9 ± 0.7% to 7.9 ± 0.7%, p < 0.05). Overall PD technique survival was prolonged
by a mean of 11.6 months (95% CI 6.0–17.3 months). On multivariate Cox proportional hazards
analysis, extension of technique survival by icodextrin was only significantly predicted by baseline
net daily peritoneal ultrafiltration (adjusted HR 2.52, 95% CI 1.13–5.62, p < 0.05).
Conclusions: Icodextrin significantly improved peritoneal ultrafiltration and extended technique
survival in PD patients with symptomatic fluid overload, especially those who had substantially
impaired peritoneal ultrafiltration.
Background
Icodextrin is an isosmolar, starch-derived, high molecu-
lar weight glucose polymer, which is minimally absorbed
across the peritoneal membrane. Two previous ran-
domised, controlled trials have shown that this agent
promotes sustained ultrafiltration and small solute
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clearances equivalent to that achieved with hypertonic
(3.86%/4.25%) glucose exchanges [1,2]. Moreover, in
subjects with higher peritoneal membrane transport
characteristics, icodextrin appears to achieve superior
fluid removal compared with glucose-based dialysates
[3,4]. Ultrafiltration is produced by colloidal, rather than
crystalline, osmotic pressure and is sustained over pro-
longed (12 to 16 hour) dwells [5]. There is also emerging
evidence that this isosmolar solution may be less damag-
ing to the peritoneal membrane than glucose-based dia-
lysates [6].
Two small, retrospective studies in CAPD patients
[7][8]have suggested that substitution of icodextrin for a
long-dwell glucose exchange may result in respective ex-
tensions of technique survival by median values of ap-
proximately 8 months [7] and 22 months [8]. However,
these studies were potentially limited by recall bias and
by the lack of a clear definition of "ultrafiltration failure,"
thereby introducing uncertainty as to the true extent of
PD prolongation. Furthermore, neither of these studies
attempted to examine which patient characteristics pre-
dicted a satisfactory ultrafiltration response to icodextrin
and subsequent enhancement of technique survival. The
aim of the present study was to prospectively evaluate
the ability of icodextrin to alleviate fluid overload and ex-
tend technique survival in PD patients on the verge of be-
ing transferred to haemodialysis because of refractory,
symptomatic fluid retention. Subsequent analyses were
also performed to determine which patients were most
likely to respond to icodextrin therapy.
Methods
Patients
All patients over the age of 18 years who were receiving
PD at the Princess Alexandra Hospital between 30 Janu-
ary 1999 and 31 May 2001 were included in the study if
they had pulmonary or peripheral oedema that was re-
fractory to a combination of (i) fluid restriction (≤  800
ml/day), (ii) frusemide therapy (≥  250 mg daily), (iii)
dwell time optimisation according to transport status,
and, (iv) hypertonic glucose exchanges (consisting of at
least one daily 4.25% exchange). All patients were con-
sidered by their treating physicians to be at the point of
transfer to haemodialysis because of refractory fluid
overload. CAPD patients had received a minimum of 4
exchanges and 8 litres of dialysis fluid per day. Those in-
dividuals on automated PD (APD) were treated with a
continuous cycling PD (CCPD) regimen consisting of at
least 12.5 L of dialysis fluid per day. Informed consent
was obtained from all patients prior to their participation
in the trial and the study protocol was reviewed and ap-
proved by the Princess Alexandra Hospital Research
Ethics Committee.
Study protocol
The study followed a prospective, open label, pre-test/
post-test design. One 12-hour 7.5% icodextrin exchange
(2.5 L Extraneal®, Baxter Healthcare, Castlebar, Ire-
land) was substituted for either one overnight (CAPD pa-
tients) or daytime (APD patients) 4.25% glucose
exchange. The remaining glucose exchanges (all 2.5%
glucose exchanges except for 2 patients who each had an
additional 4.25% glucose exchange) were not altered at
any stage. Clinical and laboratory indices of fluid reten-
tion (weight, blood pressure, serum albumin concentra-
tion, plasma sodium concentration, haemoglobin
concentration), peritoneal membrane transport status
(peritoneal equilibration test [9]) and daily net perito-
neal ultrafiltration were recorded prior to, and 1 month
after, commencing icodextrin. Glycated hamoglobin
(HbA1c) levels were additionally measured in diabetic
patients prior to, and 3 months after, commencing ico-
dextrin. The decision regarding whether subjects re-
mained on PD or were transferred to haemodialysis was
left to the discretion of their treating nephrologist. Pa-
tients were followed at monthly intervals until the end of
the study (31 May 2001), at which point data were cen-
sored.
The primary outcome measure was extension of PD tech-
nique survival, which was regarded as the time interval
between commencement of icodextrin and either PD
completion or study termination. Secondary outcome
measures included changes in daily ultrafiltration vol-
ume, indices of fluid retention, dialysate:plasma creati-
nine ratio at 4 hours (D:P Cr 4 h), and HbA1c during the
Figure 1
Kaplan-Meier technique survival curve in 17 fluid-overloaded
PD patients following commencement of icodextrin.
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initial month (or 3 months for HbA1c) of icodextrin ther-
apy.
Statistical analysis
Normality of data was evaluated by the Kolmogorov-
Smirnov test with Lilliefor's correction. Results are ex-
pressed as mean ± standard error (SEM) for continuous
parametric data, median (interquartile range) for contin-
uous non-parametric data, and frequencies and percent-
ages for categorical data. PD technique survival curves,
survival probabilities and estimated mean survival times
were generated according to the Kaplan-Meier method.
Data were not censored for death. Differences in the sur-
vival curves between the subgroups were evaluated using
the log rank test. In order to ascertain the patient charac-
teristics that independently predicted extension of PD
technique survival, a multivariate Cox proportional haz-
ards model regression analysis was subsequently per-
formed, which included age, gender, racial status,
diabetes, ultrafiltration and high transporter status as
covariates. A backward elimination procedure was car-
ried out with removal testing based on the probability of
the Wald statistic until the most parsimonious model
was identified. Adjusted survival curves were estimated
using the Cox average covariate method, which calcu-
lates predicted survival probabilities at the mean levels
of the covariates. Pre- and post-icodextrin changes in the
secondary outcome measures of daily ultrafiltration vol-
ume, fluid retention indices, D:P Cr 4 h and HbA1c were
assessed by paired t-test or Wilcoxon signed rank tests,
depending on data distribution. Data were analysed us-
ing the using the statistical software package, SPSS re-
lease version 10.0.5 (SPSS Inc., Chicago, IL). P values
less than 0.05 were considered significant.
Results
Patient characteristics
Extension of PD technique survival
Substitution of an icodextrin exchange for a glucose ex-
change was associated with a significant prolongation of
technique survival (mean 11.6 months, 95% CI 6.0–17.3
months) in patients who were otherwise about to be
transferred to haemodialysis for refractory, symptomatic
fluid overload (Fig. 1). The causes of technique failure in-
cluded fluid overload (n = 4), peritonitis (n = 1) and
death (peritonitis n = 1, acute myocardial infarction n =
1). No individuals underwent renal transplantation. Pa-
tients who had low daily ultrafiltration, defined as a net
daily ultrafiltration of less than 1 L [10], remained on PD
for a considerably longer time period following icodex-
trin administration than those who had normal daily ul-
trafiltration (Fig. 2). Using a multivariate Cox
proportional hazards model analysis, baseline daily ul-
trafiltration (L/day) was the only independent predictor
of technique survival on icodextrin (adjusted hazard ra-
tio 2.52, 95% CI 1.13–5.62, p < 0.05). Extension of time
on PD was not significantly associated with age, gender,
ethnicity, diabetes mellitus or high transporter status.
Effect of icodextrin on ultrafiltration, fluid status indices and glycae-
mic control
Prescription of icodextrin for 1 month resulted in a sig-
nificant 599 ml increase in mean daily ultrafiltration rate
and a 10 mmHg reduction in mean arterial pressure (Ta-
ble 2). Patient weight decreased from 80.8 ± 4.3 to 79.6
± 4.2 kg, but the difference did not achieve statistical sig-
nificance (p = 0.14). No significant changes were ob-
served in haemoglobin levels or serum concentrations of
sodium, chloride, osmolality, urea, creatinine and glu-
cose.
Table 1: Baseline patient characteristics. Results are presented as 
mean ± SEM, percentage or median (range), depending on data 
type.
Characteristic Value
Demographic
Age (years) 56.8 ± 2.9
Male 9 (53%)
Caucasian 9 (53%)
Weight (kg) 80.8 ± 4.3
Diabetes Mellitus 12 (71%)
Ischaemic Heart Disease 12 (71%)
Dialysis
Dialysis Duration (months) 18.6 ± 3.5
APD 5 (29%)
Prescribed Dialysate Volume (L/day) 12(8–21)
Ultrafiltration (mL/day) 855 ± 210
Residual Renal Creatinine Clearance (L/wk) 17.1 ± 5.1
Transport Status (H / HA / LA / L) 18%/71%/12%/0%
ESRF Cause
Diabetic Nephropathy 11(65%)
Chronic Glomerulonephritis 2 (12%)
Diffuse Cortical Necrosis 1 (6%)
Renovascular Nephrosclerosis 1 (6%)
Systemic Lupus Erythematosus 1 (6%)
Bladder Cancer 1 (6%)BMC Nephrology 2001, 2:2 http://www.biomedcentral.com/1471-2369/2/2
In the 12 patients with diabetes mellitus, substitution of
icodextrin for glucose in one exchange daily led to a sig-
nificant fall in HbA1c from 8.9 ± 0.7 to 7.9 ± 0.7% (p <
0.05). Seven out of 12 patients required a reduction in in-
sulin prescription, whilst dosages in the remaining pa-
tients were not changed.
Seventeen patients out of a total PD population of 263
met the inclusion criteria for the study during the 28-
month recruitment period. Their characteristics are
shown in Table 1. Compared with the general PD popula-
tion at the Princess Alexandra Hospital, patients with re-
fractory, symptomatic fluid overload had significantly
higher weights (80.8 ± 4.3 versus 72.5 ± 1.5 kg, p < 0.05),
lower daily net ultrafiltration rates (855 ± 210 versus
1310 ± 100 ml, p < 0.05) and greater frequencies of dia-
betes mellitus (71% versus 26%, p < 0.001), ischaemic
heart disease (71% versus 37%, p = 0.01) and either high
or high-average peritoneal transport characteristics
(89% versus 58%, p < 0.05). All 17 eligible subjects
agreed to participate in the study and none were lost to
follow-up. The total follow-up time on icodextrin was
98.7 patient-months.
Adverse effects
Icodextrin therapy was not associated with a significant
alteration in D:P Cr 4 h (pre-icodextrin 0.72 ± 0.05 ver-
sus post-icodextrin 0.74 ± 0.05, p = 0.55). Peritonitis
rates following the institution of icodextrin were also not
significantly different from antecedent rates (pre-ico-
dextrin 0.20 versus post-icodextrin 0.21 episodes per pa-
tient-year, p = 1.00). No skin rashes or other adverse
effects were observed.
Discussion
The results of the present study suggest that icodextrin
may play a useful role in alleviating symptomatic fluid
overload and extending technique survival in patients
who have failed PD because of intractable hypervolae-
mia. Within the first month of substituting one icodex-
trin exchange for a glucose exchange, net daily peritoneal
ultrafiltration was increased by nearly 600 ml and mean
arterial pressure fell back towards normotensive levels
by an average of 10 mmHg. The degree of symptomatic
improvement obtained was sufficient to prolong time on
PD by an average of 1 year.
These results support the previous findings of an analy-
sis by Peers et al [7] of 56 ultrafiltration failure patients
entered into a compassionate-use programme, in which
icodextrin therapy extended median technique survival
by approximately 8 months. Based on the cost differen-
tial between icodextrin-based PD and in-centre haemo-
dialysis, this translated into a saving of approximately
£1500 per year of extended PD life. A subsequent report
Table 2: Effect of prescription of icodextrin for 1 month on ultra-
filtration, fluid retention indices and selected biochemical param-
eters in 17 PD patients with refractory fluid overload. * p < 0.05 
versus baseline
Parameter Baseline 1 month Post-Ico-
dextrin
Net daily ultrafiltration (ml) 855 ± 210 1454 ± 215*
Mean arterial pressure (mmHg) 106 ± 49 6  ± 4*
Weight (kg) 80.8 ± 4.3 79.6 ± 4.2
Haemoglobin (g/L) 107 ± 3 104 ± 4
Serum albumin (g/L) 33.6 ± 1.0 32.1 ± 0.9
Serum sodium (mmol/L) 137 ± 1 136 ± 1
Serum chloride (mmol/L) 94 ± 1 93 ± 1
Serum osmolalitv (mOsm/kg) 290 ± 3 288 ± 3
Serum urea (mmol/L) 16.1 ± 1.6 16.7 ± 2.2
Serum creatinine (mmol/L) 0.80 ± 0.07 0.71 ± 0.06
Serum glucose (mmol/L) 9.8 ± 1.6 7.8 ± 1.2
Figure 2
Relataive effects of low daily ultrafiltration (LDUF, peritoneal
ultrafiltration < 1000 mL/day) and normal daily ultrafiltration
(NDUF) on icodextrin technique survival (log rank 7.2, p <
0.01).
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by Wilkie and colleagues [8] similarly demonstrated that
icodextrin extended median PD technique survival by 22
months in 33 patients with ultrafiltration failure. How-
ever, both of these retrospective studies were significant-
ly limited by the fact that there had been no a priori well-
defined indications or protocols for icodextrin adminis-
tration. Thus, the true degree of prolongation of PD tech-
nique survival was uncertain. Moreover, the univariate
survival analysis performed by Wilkie and associates [8]
was censored for mortality, even though it is conceivable
that fluid overload potentially contributed to some or all
of the 8 deaths that occurred in the study. Both of these
limitations were addressed in the present study by not
censoring PD technique survival for patient death and by
prospectively and precisely defining refractory, sympto-
matic fluid overload as a study inclusion criterion.
The extension of PD life in our study appears to have
been related to a substantial increase in peritoneal fluid
removal and was most marked in those patients who had
poor initial daily ultrafiltration (<1 L/day). For each ad-
ditional litre/day of peritoneal ultrafiltration prior to ico-
dextrin commencement, the adjusted risk of subsequent
early technique failure was increased by approximately
150%. These results are supported by Imholz et al [11],
who demonstrated that icodextrin promoted a greater
net ultrafiltration in 5 CAPD patients with low ultrafiltra-
tion than those with normal ultrafiltration (918 ± 85 vs
657 ± 104 ml, respectively, p = 0.06).
In keeping with previous studies of patients with refrac-
tory fluid overload [12–14], most (89%) of the patients in
this investigation were high or high-average transport-
ers. Their generally favourable response to icodextrin is
consistent with the reported observation in stable perito-
neal dialysis patients that the mass transfer area coeffi-
cient of creatinine was positively correlated with
transcapillary ultrafiltration induced by icodextrin, but
not glucose dialysate [3]. Similarly, Woodrow et al [4]
noted in euvolaemic CCPD patients that the difference in
daytime ultrafiltration between icodextrin and 3.86%
glucose was positively correlated with the dialysate:plas-
ma creatinine ratio, suggesting that icodextrin achieves
superior fluid removal compared with glucose-based di-
alysates in subjects with higher peritoneal membrane
transport characteristics. Such a correlation was unable
to be demonstrated in our patients with symptomatic
fluid overload, possibly because of the great preponder-
ance of high and high-average transporters and the con-
sequent narrowing of the range of dialysate:plasma
creatinine ratios.
Inadequate ultrafiltration contributes directly to 8% of
PD technique failure in Australia and New Zealand [15]
and probably indirectly to an even larger number of pa-
tients. The risk of ultrafiltration failure increases pro-
gressively with time on dialysis and has been reported to
be as high as 31% by 6 years [12]. It is possible to extend
time on PD to a limited extent by increasing the number
of hypertonic (3.86%/4.25%) glucose exchanges, but this
is believed to cause further peritoneal damage [16]. Ico-
dextrin on the other hand, has been shown to promote
equivalent or superior ultrafiltration to glucose PD solu-
tions, whilst avoiding the local and systemic sequelae of
peritoneal glucose exposure [1,2,6,17–19]. The improve-
ment in peritoneal ultrafiltration per gram of carbohy-
drate absorbed seen with icodextrin may be particularly
advantageous to diabetic PD patients, who have an in-
creased risk of type I ultrafiltration failure [20–24] and
who frequently experience destabilisation of their gly-
caemic control following the use of hypertonic glucose
dialysis solutions. Our study indicated that exchanging
icodextrin for glucose dialysate resulted in a reduction in
both insulin requirements and HbA1c levels in hypervol-
aemic diabetic PD patients. This issue has not been pre-
viously formally evaluated in icodextrin trials.
One of the weaknesses of our study is the lack of a paral-
lel control group, which makes it difficult to be precise
about the degree of extra PD time that was afforded by
commencing icodextrin therapy. However, there clearly
was a pronounced extension of PD technique survival in
this well-defined group of patients with refractory fluid
overload who had failed glucose-based dialysis. The im-
portant question that remains unanswered by this study
is whether patient outcomes are optimised by giving
such individuals a trial of icodextrin therapy or immedi-
ately transferring them to haemodialysis.
Conclusions
Icodextrin can significantly augment peritoneal ultrafil-
tration, alleviate fluid overload, improve diabetic glycae-
mic control and extend technique survival in PD patients
with refractory, symptomatic fluid overload. Those indi-
viduals with low net daily ultrafiltration volumes (< 1 L/
day) appear to be more likely to derive benefit from in-
corporation of icodextrin into their PD regimens than
patients with higher ultrafiltration volumes.
List of abbreviations
APD Automated peritoneal dialysis
CAPD Continuous ambulatory peritoneal dialysis
CCPD Continuous cycling peritoneal dialysis
D:P Cr 4 h Dialysate:plasma creatinine ratio at 4 hours
HbA1c Glycated haemoglobinBMC Nephrology 2001, 2:2 http://www.biomedcentral.com/1471-2369/2/2
LDUF Low daily ultrafiltration
NDUF Normal Daily ultrafiltration
PD Peritoneal dialysis
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